You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a Nutraceutical Product against Ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation
SBC: NEWVENTUREIQ LLC Topic: NIAIDABSTRACT Human leukocyte antigenHLAtyping is an essential laboratory test to evaluate the donor recipient compatibility before life saving transplantationsInaloneHLA typing of donors and recipients guided overorgan and stem cell transplantations in the United StatesExisting high resolution HLA typing methods require a turnaround time of days to weeksThere has been an unmet clinical need for a rapi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biologically Targeted Vaccine for Chikungunya
SBC: PRECISION VIROLOGICS INC Topic: NIAIDPROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Micro-endoscopic impedance sensing for surgical margin assessment
SBC: RYTEK MEDICAL INC Topic: 102ABSTRACT The primary objective of surgical therapy for the treatment of patients with any cancer is to remove all cancer cells from within the bodywith the secondary objective of maintaining organ functionThe primary pathological metric used to rate the success of a surgical procedure is evaluation of the surgical margin of the resected tissue specimenpost operativelyThis typically involves cuttin ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.
SBC: EARNANO LLC Topic: NICHDOtitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a bioconjugate vaccine against Group B Streptococcus
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non-pregnant adults. GBS neonatal disease manifests as early onset, defined as disease within the first six days after birth, or late onset, defined as disease occurring after the f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
An unobtrusive monitoring device used for tracking asthma symptoms and lungfunction variability
SBC: CLAIRWAYS LLC Topic: NHLBIExecutive Summary of Predicate (One Page) Summary of Specific Aims of Phase I Specific Aim 1: Train and evaluate an algorithm to detect pediatric asthma symptoms (cough and wheeze) on a low power, small form factor wearable device. Specifications: 90% sensitivity; false alarm rate: 1 cough episode/day or 1 wheeze episode/day. Evaluate algorithm against medical expert (physician) scoring using the ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Use of mimotope vaccine technology to develop vaccines against bacterial pathogens
SBC: ZenVax LLC Topic: NIAIDABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE
SBC: Mitochondria in Motion, Inc. Topic: 999Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: There are a number of rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), for which there is no available or effective therapy and which lead to significant mor ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health